SciELO - Scientific Electronic Library Online

 
vol.30 issue2Pharmacogenetic response to escitalopram in geriatric patients in GuatemalaGalenic aspects of submucosal injection solutions for use in endoscopic polypectomy author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la OFIL

On-line version ISSN 1699-714XPrint version ISSN 1131-9429

Abstract

SCOLARI, MJ. Rediscovering old acquaintances: the possible role of hydroxychloroquine, chloroquine, ivermectin, and teicoplanin in the treatment of COVID-19. Rev. OFIL·ILAPHAR [online]. 2020, vol.30, n.2, pp.127-130.  Epub Mar 15, 2021. ISSN 1699-714X.  https://dx.doi.org/10.4321/s1699-714x2020000200012.

The coronavirus (COVID-19) pandemic triggered in China in December 2019 represents a global therapeutic challenge. To date, a wide variety of drugs, with potential to treat the disease, have been proposed. The vast majority of them, are medications that existed, prior to the pandemic, used to treat other pathologies. However, none has demonstrated to be effective in well designed clinical trials that specifically endorse its use for COVID-19. In this context, their cost and availability becomes a fundamental factor, particularly in Latin America. This article will review key characteristics of known and affordable medications in Argentina and the rest of Latin America: hydroxychloroquine, chloroquine, ivermectin and teicoplanin.

Keywords : Coronavirus; hydroxychloroquine; chloroquine; ivermectin; teicoplanin.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )